Don't let colon cancer outsmart you - get tested Sun-Sentinel.com, FL - Nov 4, 2008 *People whose relatives have had breast or ovarian cancer -- which have been linked to colon cancer. Most symptoms aren't noticeable until the disease is ...
Curing Diversity FrontPage magazine.com, CA - Nov 27, 2008 In the past decade, according to one recent study, 25 trials of drugs that treat cancer of the breast, bowel, lung, kidney, ovary, and gastrointestinal ...
Prevention is better than the cure for cancer Merinews, India - Nov 17, 2008 Aspirin based mainly on experimental data, the regular use of aspirin as a preventive for stomach cancer has been advanced. However, the human evidence of a ...
Source: Google News
Recent News and Articles on the Keywords: cancer + ovarian + responds Related to the article below (Last Update: 8/7/2008)
How Chemo Kills Tumors: Research To Reduce Side Effects Science Daily (press release) - He and Ms Gascoigne, whose findings are published in the journal Cancer Cell (August 2008), have shown how different tumours respond to the anti-mitotic ...
Study Finds Vitamin C May Stop Cancer Growth NBC 10.com, PA - Aug 5, 2008 "We've found it to be very helpful in cases of breast cancer, ovarian cancer, lung, colon cancer lymphoma and other bone marrow cancer," Greenberg said. ...
Craig W. Philips Takes Helm at CTI FOXBusiness - Aug 5, 2008 OPAXIO is also being studied independently in a phase III trial for ovarian cancer, with interim data results expected in late 2009. ...CTIC - OTC:CMTX
Danville Weekly Online Calendar Danville Weekly, CA - ... for all types of cancer patients as well as cancer specific groups for breast cancer, colorectal cancer, ovarian cancer, lung cancer, prostate cancer, ...
OxiGene, Inc. Q2 2008 Earnings Call Transcript Seeking Alpha, NY - Aug 4, 2008 There is a very high unmet need for new and effective treatments for platinum-resistant ovarian cancer as the therapeutic options for these patients are ...OXGN
Bespoke cancer therapy raises vital question of cost Times Online, UK - Jul 21, 2008 It is often said that this is already the case for prostate cancer, as about 70 per cent of cases respond well to treatment with chemical castration to ...
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and … - FM Muggia, JD Hainsworth, S Jeffers, P Miller, S … - Journal of Clinical Oncology, 1997 - jco.ascopubs.org ...ovariancancer who failed to respond to platinum ... and activity in refractory ovarian cancer patients that ... clinical responses (one complete response [CR], eight ...
Second-Line Treatment of Ovarian Cancer - M Markman, MA Bookman - The Oncologist, 2000 - theoncologist.org ... of second-line therapy in ovariancancer have been ... II noncomparative studies with
objective response rates in ... some patients may continue to respond or maintain ...
Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer - P Francis, J Schneider, L Hann, C Balmaceda, R … - Journal of Clinical Oncology, 1994 - jco.ascopubs.org ... and five had failed to respond to platinum ... The median response duration was 5 months. ...
activity in patients with platinum-refractory advanced ovariancancer. ...
The biology of ovarian cancer. - N Auersperg, MI Edelson, SC Mok, SW Johnson, TC … - Semin Oncol, 1998 - ncbi.nlm.nih.gov ... The biology of ovariancancer broadly defined covers essentially all aspects of
the disease from how it arises to how it responds to chemotherapy, often ...
Future directions in the treatment of ovarian cancer. - RF Ozols - Semin Oncol, 2002 - ncbi.nlm.nih.gov ... patients with advanced ovariancancer consists of the combination of a taxane and
a platinum compound. While the majority of patients respond to therapy ...
Source: Google Scholar
Ovarian cancer responds to Aspirin derivative with Cisplatin
A study using ovarian cancer cell lines showed promise in treating tumor by combining the chemotherapy drug Cisplatin with an Aspirin-like compound to make recurrent cancer cells less resistant to the chemotherapy.
The study is published in the Proceedings of the National Academy of Sciences ( PNAS ).
As a first course of treatment, ovarian cancer typically is treated with surgery followed by a regimen of the chemotherapy drug Cisplatin.
However, Cisplatin is not an effective treatment when the ovarian cancer inevitably returns, says Periannan Kuppusamy, at the Ohio State University Comprehensive Cancer Center.
" Somehow the ovarian cancer cells adapt and become resistant to this drug," said Kuppusamy, lead author of the study. " Once treated with Cisplatin, the ovarian cancer cells develop an abundance of thiols, which are a kind of cellular antioxidants that protect the cancer from the chemotherapy."
Kuppusamy wondered whether the abundance of thiols could somehow be used against the ovarian cancer cells. The study found that the nitric oxide released from the Aspirin derivative NCX-4016 reacts with the cellular thiols, which causes the cancer cells to stop proliferating. In addition, the nitric oxide depletes the thiols, making the cancer cells more susceptible to the chemotherapy.
" The nitric oxide-releasing ability of the aspirin derivative NCX-4016 is enhanced by thiols, so I thought this type of treatment might work better in a tumor cancer cell that is rich in thiols, such as a resistant ovarian cancer," Kuppusamy said.
